SI3233852T1 - Tetrahidro-pirido(3,4-b)indoli kot modulatorji estrogenskih receptorjev in njihove uporabe - Google Patents

Tetrahidro-pirido(3,4-b)indoli kot modulatorji estrogenskih receptorjev in njihove uporabe

Info

Publication number
SI3233852T1
SI3233852T1 SI201531344T SI201531344T SI3233852T1 SI 3233852 T1 SI3233852 T1 SI 3233852T1 SI 201531344 T SI201531344 T SI 201531344T SI 201531344 T SI201531344 T SI 201531344T SI 3233852 T1 SI3233852 T1 SI 3233852T1
Authority
SI
Slovenia
Prior art keywords
indoles
pyrido
tetrahydro
estrogen receptor
receptor modulators
Prior art date
Application number
SI201531344T
Other languages
English (en)
Inventor
Simon Charles Goodacre
Sharada Labadie
Jun Liang
Daniel Fred Ortwine
Nicholas Charles Ray
Xiaojing Wang
Jason Zbieg
Birong Zhang
Kwong Wah Lai
Jiangpeng Liao
Zhiguo Liu
John Sui-Man Wai
Tao Wang
Jun Li
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI3233852T1 publication Critical patent/SI3233852T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SI201531344T 2014-12-18 2015-12-17 Tetrahidro-pirido(3,4-b)indoli kot modulatorji estrogenskih receptorjev in njihove uporabe SI3233852T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462093929P 2014-12-18 2014-12-18
US201562110998P 2015-02-02 2015-02-02
US201562142077P 2015-04-02 2015-04-02
EP15810660.9A EP3233852B1 (en) 2014-12-18 2015-12-17 Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereof
PCT/EP2015/080119 WO2016097072A1 (en) 2014-12-18 2015-12-17 TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Publications (1)

Publication Number Publication Date
SI3233852T1 true SI3233852T1 (sl) 2020-10-30

Family

ID=54850193

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531344T SI3233852T1 (sl) 2014-12-18 2015-12-17 Tetrahidro-pirido(3,4-b)indoli kot modulatorji estrogenskih receptorjev in njihove uporabe

Country Status (33)

Country Link
US (3) US9980947B2 (sl)
EP (2) EP3233852B1 (sl)
JP (4) JP6679147B2 (sl)
KR (2) KR102559719B1 (sl)
CN (5) CN107108611B (sl)
AU (3) AU2015367509B2 (sl)
BR (1) BR112017007662B1 (sl)
CA (1) CA2963736A1 (sl)
CL (2) CL2017000814A1 (sl)
CO (1) CO2017003070A2 (sl)
CR (1) CR20170250A (sl)
DK (1) DK3233852T3 (sl)
EA (1) EA032311B1 (sl)
ES (1) ES2819448T3 (sl)
HK (1) HK1243074A1 (sl)
HR (1) HRP20201396T1 (sl)
HU (1) HUE050466T2 (sl)
IL (5) IL287326B2 (sl)
LT (1) LT3233852T (sl)
MA (1) MA53837A (sl)
MX (3) MX2017007489A (sl)
MY (1) MY198354A (sl)
NZ (1) NZ769496A (sl)
PE (1) PE20171330A1 (sl)
PH (1) PH12017501140A1 (sl)
PL (1) PL3233852T3 (sl)
PT (1) PT3233852T (sl)
RS (1) RS60824B1 (sl)
SG (3) SG10201913913VA (sl)
SI (1) SI3233852T1 (sl)
TW (3) TWI699363B (sl)
UA (1) UA122868C2 (sl)
WO (1) WO2016097072A1 (sl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015279047B2 (en) 2014-06-27 2020-01-02 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
NZ769496A (en) 2014-12-18 2023-09-29 Hoffmann La Roche Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
AU2016331065B2 (en) 2015-10-01 2021-04-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
CN108495628B (zh) 2015-12-09 2022-01-11 伊利诺伊大学评议会 苯并噻吩基选择性***受体下调剂
EP3411034B1 (en) * 2016-02-05 2020-11-25 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
BR112018016490A2 (pt) 2016-02-15 2018-12-18 Sanofi derivados de 6,7-di-hidro-5h-benzo[7]anuleno como moduladores de receptor de estrogênio
WO2017182493A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3454862A4 (en) 2016-05-10 2020-02-12 C4 Therapeutics, Inc. SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
EP3472159A1 (en) * 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN107543871A (zh) * 2016-06-29 2018-01-05 重庆华邦胜凯制药有限公司 分离测定帕布昔利布中间体z1及其有关物质的方法
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
TW201815789A (zh) * 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
WO2018064231A1 (en) * 2016-09-27 2018-04-05 Radius Health, Inc. Methods for treating ovarian cancer
EP3640251B1 (en) * 2016-10-24 2021-12-08 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CN110139863B (zh) * 2016-10-28 2022-02-18 罗欣健康科技发展(北京)有限公司 作为***受体降解剂的吲哚并取代哌啶类化合物
AU2017362460B2 (en) * 2016-11-17 2021-07-22 Sanofi Novel substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
EA037533B9 (ru) * 2016-12-16 2021-05-27 Астразенека Аб 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
AR110728A1 (es) 2017-01-06 2019-04-24 G1 Therapeutics Inc Terapia combinada para el tratamiento del cáncer
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性***受体下调剂的五环类化合物及其应用
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
BR112019015389A2 (pt) 2017-01-30 2020-03-10 Astrazeneca Ab Moduladores de receptores de estrogênio
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
EA201992768A1 (ru) 2017-06-29 2020-05-19 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
WO2019096106A1 (zh) * 2017-11-14 2019-05-23 杭州安霖药业有限公司 杂环化合物及其在医药上的应用
EA038160B1 (ru) * 2017-11-30 2021-07-15 Астразенека Аб Модуляторы рецептора эстрогена
US10519152B2 (en) 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的***受体降解剂
HUE064542T2 (hu) * 2018-06-21 2024-03-28 Hoffmann La Roche A 3-((1R,3R)1(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9 -tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropán-1-ol tartarátsó szilárd formái, eljárás elõállításukra és rákos megbetegedések kezelésében történõ alkalmazási módszereik
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性***受體降解劑
JP7413363B2 (ja) 2018-09-07 2024-01-15 サノフイ メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
AU2020228385A1 (en) * 2019-02-27 2021-07-29 Takeda Pharmaceutical Company Limited Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113993845A (zh) * 2019-06-17 2022-01-28 优时比制药有限公司 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
JP2022540421A (ja) * 2019-07-07 2022-09-15 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
CA3148221A1 (en) 2019-08-06 2021-02-11 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
WO2021055749A1 (en) * 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
TW202140475A (zh) * 2020-01-16 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合醯亞胺類衍生物、其製備方法及其在醫藥上的應用
WO2021143822A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 并环酰亚胺类衍生物、其制备方法及其在医药上的应用
WO2021178846A1 (en) * 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2021213358A1 (zh) * 2020-04-21 2021-10-28 江苏先声药业有限公司 含硼化合物及其应用
MX2022014133A (es) * 2020-05-12 2022-11-30 Genentech Inc Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6.
JP7419503B2 (ja) 2020-06-30 2024-01-22 ジェネンテック， インコーポレイテッド 置換フェニル又はピリジニル部分を有するｓｅｒｄ三環化合物の製造方法
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 ***受体调节剂化合物及其用途
WO2022140744A1 (en) * 2020-12-23 2022-06-30 Recurium Ip Holdings, Llc Estrogen receptor modulators
CN116744920A (zh) * 2021-02-08 2023-09-12 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
WO2023284837A1 (zh) * 2021-07-15 2023-01-19 四川海思科制药有限公司 芳氨基衍生物***受体调节剂及其用途
WO2023083283A1 (zh) * 2021-11-12 2023-05-19 先声药业有限公司 用于***的药物组合及其应用
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023125700A1 (zh) * 2021-12-28 2023-07-06 南京明德新药研发有限公司 四氢环庚吲唑化合物的盐型、晶型
WO2023209062A1 (en) 2022-04-28 2023-11-02 F. Hoffmann-La Roche Ag Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024017131A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
CN115109058B (zh) * 2022-07-27 2023-04-07 黑龙江中医药大学 一种用于治疗胃癌的药物及其制备方法
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024039860A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024039858A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2024042163A1 (en) * 2022-08-25 2024-02-29 Sanofi Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
CN115894485B (zh) * 2023-03-03 2023-06-27 山东绿叶制药有限公司 杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
US11773092B1 (en) 2023-03-27 2023-10-03 King Faisal University Pyrido[3,4-b]indol-1-one compounds as antibacterial agents

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE398789C (de) 1923-03-03 1924-07-15 L V Kramolin Verfahren und Einrichtung zur Verhinderung des Mithoerens beim Telephon- und Telegraphenverkehr mittels elektrischer Wellen und zum Vielfachverkehr mittels elektromagnetischer Wellen
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
WO2002062339A1 (en) 2000-12-08 2002-08-15 Smithkline Beecham Corporation Antibacterial compounds
ES2248412T3 (es) 2001-02-12 2006-03-16 Lilly Icos Llc Derivados de carbolina.
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2004089470A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
WO2005034857A2 (en) 2003-09-05 2005-04-21 Sequella, Inc. Methods and compositions comprising diamines as new anti-tubercular therapeutics
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
NZ588388A (en) 2004-03-15 2012-05-25 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US20080103164A1 (en) 2004-08-02 2008-05-01 Kristjan Gudmundsson Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
US7514444B2 (en) 2006-09-22 2009-04-07 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
ES2447590T3 (es) 2008-04-29 2014-03-12 Novartis Ag Derivados de espiro-indol para el tratamiento de enfermedades parasitarias
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
US20110195929A1 (en) 2008-08-05 2011-08-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
CA2756808A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-piperidine compounds
MX348817B (es) * 2009-05-27 2017-06-30 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
WO2010138695A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
WO2011150162A1 (en) 2010-05-27 2011-12-01 Ptc Therapeutics, Inc. Methods for treating viral conditions
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
RS53768B1 (en) * 2010-12-16 2015-06-30 F. Hoffmann-La Roche Ag. TRICYCLIC PI3K INHIBITORS AND USE PROCEDURES
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
JP2015500346A (ja) 2011-12-14 2015-01-05 セラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその使用
DK2828385T3 (en) 2012-03-23 2018-03-12 Codexis Inc BIOCATALIZATORS AND METHODS FOR SYNTHETIZING DERIVATIVES AND TRYPTAMIN AND TRYPTAMINE ANALOGS
PL2828256T3 (pl) 2012-03-23 2019-12-31 Novartis Ag Chemiczny sposób wytwarzania spiroindolonów i ich związków pośrednich
DE102012209622A1 (de) 2012-06-08 2013-12-12 Robert Bosch Gmbh Zahnradmaschine mit hydrodynamisch und hydrostatisch gelagertem Lagerzapfen
EP2682119A1 (en) 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
EP2738173A1 (en) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Heterocyclic compounds as inhibitors of the sodium iodide symporter
BR112015029455A8 (pt) 2013-05-28 2020-03-17 Astrazeneca Ab compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer
AU2014281511A1 (en) 2013-06-19 2015-12-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
CN105848655B (zh) 2013-10-28 2019-11-08 德雷克塞尔大学 用于注意力和认知障碍的、以及用于与神经变性障碍相关联的痴呆的新疗法
CN105916501A (zh) 2013-12-06 2016-08-31 豪夫迈·罗氏有限公司 用于治疗局部晚期或转移性***受体阳性乳腺癌的***受体调节剂
AU2015228859A1 (en) 2014-03-13 2016-07-07 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
EP3116496A1 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Methods and compositions for modulating estrogen receptor mutants
AU2015279047B2 (en) 2014-06-27 2020-01-02 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
NZ769496A (en) 2014-12-18 2023-09-29 Hoffmann La Roche Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
AU2016331065B2 (en) 2015-10-01 2021-04-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs
EP3411034B1 (en) 2016-02-05 2020-11-25 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof

Also Published As

Publication number Publication date
CA2963736A1 (en) 2016-06-23
AU2020200407A1 (en) 2020-02-13
PE20171330A1 (es) 2017-09-13
CO2017003070A2 (es) 2017-07-11
IL301960B1 (en) 2024-04-01
EA201791239A8 (ru) 2019-01-31
CN112457310A (zh) 2021-03-09
MX2020003532A (es) 2020-07-29
TW202323253A (zh) 2023-06-16
TW201636348A (zh) 2016-10-16
BR112017007662A2 (pt) 2017-12-19
CN112375078A (zh) 2021-02-19
IL301960A (en) 2023-06-01
US10966963B2 (en) 2021-04-06
IL287326B1 (en) 2023-05-01
NZ730448A (en) 2021-02-26
LT3233852T (lt) 2020-10-12
HRP20201396T1 (hr) 2020-11-27
IL251370B (en) 2020-02-27
UA122868C2 (uk) 2021-01-13
JP6679147B2 (ja) 2020-04-15
MY198354A (en) 2023-08-28
PL3233852T3 (pl) 2020-12-14
IL287326B2 (en) 2023-09-01
CN117865872A (zh) 2024-04-12
CR20170250A (es) 2017-07-19
ES2819448T3 (es) 2021-04-16
IL251370A0 (en) 2017-05-29
TWI784255B (zh) 2022-11-21
DK3233852T3 (da) 2020-09-14
RS60824B1 (sr) 2020-10-30
EA201791239A1 (ru) 2017-10-31
IL270653B (en) 2021-12-01
US9980947B2 (en) 2018-05-29
JP7446348B2 (ja) 2024-03-08
MX2022007975A (es) 2022-07-05
JP7128169B2 (ja) 2022-08-30
BR112017007662A8 (pt) 2021-10-05
EA032311B1 (ru) 2019-05-31
PT3233852T (pt) 2020-09-10
US20230045776A9 (en) 2023-02-09
IL287326A (en) 2021-12-01
EP3233852B1 (en) 2020-07-15
JP2017538725A (ja) 2017-12-28
KR102559719B1 (ko) 2023-07-26
JP2022088416A (ja) 2022-06-14
EP3760623A1 (en) 2021-01-06
TW202028204A (zh) 2020-08-01
US20180235945A1 (en) 2018-08-23
KR20230113416A (ko) 2023-07-28
AU2015367509A1 (en) 2017-04-13
US20210236473A1 (en) 2021-08-05
JP2020073493A (ja) 2020-05-14
MA53837A (fr) 2021-11-10
KR20170097651A (ko) 2017-08-28
CN107108611A (zh) 2017-08-29
IL311006A (en) 2024-04-01
TWI699363B (zh) 2020-07-21
SG10201913913VA (en) 2020-03-30
HUE050466T2 (hu) 2020-12-28
CN107108611B (zh) 2020-09-25
AU2015367509B2 (en) 2020-01-02
CL2017000814A1 (es) 2017-12-29
SG10202100799PA (en) 2021-03-30
JP2024028785A (ja) 2024-03-05
AU2021200352A1 (en) 2021-03-18
CN112375078B (zh) 2023-12-19
AU2021200352B2 (en) 2022-12-15
CN112375077A (zh) 2021-02-19
AU2020200407B2 (en) 2021-04-08
CL2019000431A1 (es) 2019-07-12
BR112017007662B1 (pt) 2021-11-03
WO2016097072A1 (en) 2016-06-23
NZ769496A (en) 2023-09-29
US20160175289A1 (en) 2016-06-23
MX2017007489A (es) 2017-10-18
PH12017501140A1 (en) 2018-03-05
EP3233852A1 (en) 2017-10-25
HK1243074A1 (zh) 2018-07-06
SG11201704401TA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
IL287326B1 (en) Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses
HK1247199A1 (zh) ***受體調節劑及其用途
IL258363B (en) Tetrahydro-h1-pyrido[4,3-b]indole anti-estrogenic drugs
EP3404169A4 (en) GONDOLE DEVICE
IL247250A0 (en) Methods and compositions for modulating estrogen receptor mutants
PL3490565T3 (pl) Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
EP3267139A4 (en) Turbulence generating device
EP3212562A4 (en) Beverage supply apparatus
EP3212563A4 (en) Beverage supply apparatus
EP3186225A4 (en) Cannabinoid type 1 receptor modulators
EP3224261A4 (en) Opioid receptor modulators
EP3196609A4 (en) Dispersion and supply device and combination weighing device
EP3237102A4 (en) Device for cavitational mixing
EP3112825A4 (en) Combination weighing apparatus
EP3098580A4 (en) Combination weighing apparatus
EP3101398A4 (en) Combination weighing apparatus
EP3098298A4 (en) Cell-seeding and -culturing device
PT3157912T (pt) Composições parasiticidas compreendendo derivados de indole, seus métodos e suas utilizações
EP3149380A4 (en) Swivel device
IL252753A0 (en) History of indole and azaindole, their preparation and use
EP3224230A4 (en) Estrogen receptor modulators
WO2015196144A3 (en) Androgen receptor antagonists
AU2014900480A0 (en) Mixing apparatus
AU2014900105A0 (en) Skirt Securing Device